Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423709 · ClinicalTrials.gov registry record · NA
Allogeneic Blood Stem Cell Transplantation
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
NCT00423709: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00423709 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00423709, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
Study Summary
1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved with this strategy. 3. To assess the antitumor activity of this approach in high-risk HD patients and the possible presence of a graft-vs-HD effect.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- PROCEDURE Allogeneic Blood Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1998-01 |
| Est. Completion | 2007-08 |
| Phase | NA |
What the finished NCT00423709 record still lists
NCT00423709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00423709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00423709 about?
NCT00423709 is a clinical study titled "Allogeneic Blood Stem Cell Transplantation". 1. To determine the feasibility and toxicity of employing allogeneic peripheral blood stem cell transplantation after intensive but non-myeloablative chemotherapy in patients with relapsed Hodgkin's disease (HD). 2. To determine the engraftment kinetics and degree of chimerism that can be achieved w...
What is the current status of trial NCT00423709?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 1998-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00423709?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Allogeneic Blood Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00423709?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00423709's enrollment target sits among peer trials
46 1402nd of 2000 higher than 590 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia